Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 43, Issue 1-3, 1992, Pages 161-165

  Falkson, Geoffrey ^a   Raats, Johann I ^a   Falkson, HendréC ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FADROZOLE;

ANOREXIA; BREAST CANCER; CONFERENCE PAPER; FATIGUE; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; AROMATASE; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FADROZOLE; FEMALE; HUMAN; IMIDAZOLES; MIDDLE AGE; NITRILES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0026630462     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(92)90202-T     Document Type: Article

References (24)

1. Aromatase inhibitors: basic and clinical studies
2. Aromatase inhibitors and their potential clinical significance
3. Sterioselective inhibition of cholesterol side chain cleavage by enantiomers of aminoglutethimide
4. Low dose aminoglutethimide and aromatase inhibition
5. Aromatase inhibitors in the treatment of advanced breast cancer
6. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione
7. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients
8. In-vitro and in-vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A
9. A phase I trial of CGS 16949A. A new aromatase inhibitor
10. Clinical trials with the aromatase inhibitor CGS 16949A in advanced breast cancer: the U.S. experience
11. Aromatase activity in primary and metastatic human breast cancer
12. A study of fadrozole (CGS 16 949A), a new aromatase inhibitor, in post menopausal women with advanced metastatic breast cancer
13. Toxicity and response criteria of the Eastern Cooperative Oncology Group
14. Planning and reporting of clinical trials
15. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives
16. Aromatization of androgens by muscle and adipose tissue in vivo
17. Methods and results of aromatization studies in vivo
18. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors
19. The role of aromatase inhibitors in breast cancer
20. Could aminoglutethimide replace adrenalectomy?
21. Aminoglutethimide in the treatment of advanced breast cancer
22. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer
23. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer